Intra-Cellular TherapiesITCI
ITCI
About: Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Employees: 561
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
86% more call options, than puts
Call options by funds: $27.3M | Put options by funds: $14.7M
43% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 10 (+3) [Q3]
6% more repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 125
2% more capital invested
Capital invested by funds: $6.71B [Q2] → $6.87B (+$159M) [Q3]
4.1% less ownership
Funds ownership: 92.85% [Q2] → 88.75% (-4.1%) [Q3]
6% less funds holding
Funds holding: 370 [Q2] → 348 (-22) [Q3]
34% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 65
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$89
4%
upside
Avg. target
$98
14%
upside
High target
$108
26%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
JP Morgan Jessica Fye 46% 1-year accuracy 19 / 41 met price target | 4%upside $89 | Overweight Maintained | 4 Nov 2024 |
Needham Ami Fadia 35% 1-year accuracy 54 / 154 met price target | 17%upside $100 | Buy Reiterated | 31 Oct 2024 |
Morgan Stanley Jeffrey Hung 35% 1-year accuracy 6 / 17 met price target | 11%upside $95 | Overweight Maintained | 11 Oct 2024 |
RBC Capital Brian Abrahams 15% 1-year accuracy 12 / 79 met price target | 26%upside $108 | Outperform Maintained | 4 Oct 2024 |
Financial journalist opinion
Based on 5 articles about ITCI published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting
Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder
Positive
Seeking Alpha
2 weeks ago
Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move
CAPLYTA showed strong revenue growth, with Q3 2024 net product revenues of $125.8 million, which was a 39% year-over-year increase. Potential revenue boost if CAPLYTA's label is expanded to include it as an adjunctive therapy for major depressive disorder, addressing a significant unmet need. Lenrispodun, a PDE inhibitor, is in a phase 2 study for Parkinson's Disease, with potential data release by late 2025/early 2026, offering another blockbuster opportunity.
Positive
Zacks Investment Research
3 weeks ago
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.
Neutral
GlobeNewsWire
3 weeks ago
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
BEDMINSTER, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced that it has recently submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for CAPLYTA (lumateperone) for the treatment of Major Depressive Disorder (MDD) in adults, as adjunctive therapy to antidepressants.
Positive
Zacks Investment Research
3 weeks ago
Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
Neutral
GlobeNewsWire
1 month ago
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:
Neutral
GlobeNewsWire
1 month ago
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
Positive
Reuters
1 month ago
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial
Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.
Neutral
Seeking Alpha
1 month ago
Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder, Chairman and CEO Mark Neumann - EVP and CCO Sanjeev Narula - CFO Suresh Durgam - EVP and CMO Conference Call Participants Andrew Tsai - Jefferies Jessica Fye - JPMorgan Charles Duncan - Cantor Jason Gerberry - Bank of America Securities Jeff Hung - Morgan Stanley Michael DiFiore - Evercore David Amsellem - Piper Sandler Joel Beatty - Baird Corinne Johnson - Goldman Sachs Operator Good day and thank you for standing by. Welcome to Intra-Cellular Therapies 3Q 2024 Earnings Conference Call.
Positive
Zacks Investment Research
1 month ago
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
Charts implemented using Lightweight Charts™